FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313362220> ?p ?o ?g. }

• W4313362220 endingPage "85" @default.
• W4313362220 startingPage "85" @default.
• W4313362220 abstract "The Corona Virus Infectious Disease-2019 (COVID-19) outbreak originated at Wuhan, China, in December 2019. It has already spread rapidly and caused more than 6.5 million deaths worldwide. Its causal agent is a beta-coronavirus named SARS-CoV-2. Many efforts have already been made to develop new vaccines and drugs against these viruses, but over time, it has changed its molecular nature and evolved into more lethal variants, such as Delta and Omicron. These will lead us to target its more-conserved proteins. The sequences’ BLAST and crystal structure of the main protease Mpro suggest a high sequence and structural conservation. Mpro is responsible for the proteolytic maturation of the polyprotein essential for the viral replication and transcription, which makes it an important drug target. Discovery of new drug molecules may take years before getting to the clinics. So, considering urgency, we performed molecular docking studies using FDA-approved drugs to identify molecules that could potentially bind to the substrate-binding site and inhibit SARS-CoV-2’s main protease (Mpro). We used the Glide module in the Schrödinger software suite to perform molecular docking studies, followed by MM-GBSA-based energy calculations to score the hit molecules. Molecular docking and manual analysis suggest that several drugs may bind and potentially inhibit Mpro. We also performed molecular simulations studies for selected compounds to evaluate protein–drug interactions. Considering bioavailability, lesser toxicity, and route of administration, some of the top-ranked drugs, including lumefantrine (antimalarial), dipyridamole (coronary vasodilator), dihydroergotamine (used for treating migraine), hexoprenaline (anti asthmatic), riboflavin (vitamin B2), and pantethine (vitamin B5) may be taken forward for further in vitro and in vivo experiments to investigate their therapeutic potential." @default.
• W4313362220 created "2023-01-06" @default.
• W4313362220 creator A5003094483 @default.
• W4313362220 creator A5032228746 @default.
• W4313362220 creator A5069479089 @default.
• W4313362220 creator A5090298658 @default.
• W4313362220 date "2022-12-29" @default.
• W4313362220 modified "2023-09-24" @default.
• W4313362220 title "Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies" @default.
• W4313362220 cites W10734288 @default.
• W4313362220 cites W184913305 @default.
• W4313362220 cites W1983274930 @default.
• W4313362220 cites W1984379900 @default.
• W4313362220 cites W1984670037 @default.
• W4313362220 cites W1994915168 @default.
• W4313362220 cites W1998723973 @default.
• W4313362220 cites W2004343588 @default.
• W4313362220 cites W2006286994 @default.
• W4313362220 cites W2007991289 @default.
• W4313362220 cites W2009423060 @default.
• W4313362220 cites W2025458374 @default.
• W4313362220 cites W2035205419 @default.
• W4313362220 cites W2064236558 @default.
• W4313362220 cites W2071235764 @default.
• W4313362220 cites W2079953901 @default.
• W4313362220 cites W2095719702 @default.
• W4313362220 cites W2102377211 @default.
• W4313362220 cites W2105641709 @default.
• W4313362220 cites W2112038600 @default.
• W4313362220 cites W2127559900 @default.
• W4313362220 cites W2130200870 @default.
• W4313362220 cites W2148767282 @default.
• W4313362220 cites W2149319510 @default.
• W4313362220 cites W2153228625 @default.
• W4313362220 cites W2161572568 @default.
• W4313362220 cites W2162569125 @default.
• W4313362220 cites W2162800127 @default.
• W4313362220 cites W2168621448 @default.
• W4313362220 cites W2168974130 @default.
• W4313362220 cites W2222589778 @default.
• W4313362220 cites W2411675557 @default.
• W4313362220 cites W2513547424 @default.
• W4313362220 cites W2762161295 @default.
• W4313362220 cites W2808651110 @default.
• W4313362220 cites W2916300783 @default.
• W4313362220 cites W2922684335 @default.
• W4313362220 cites W2947642275 @default.
• W4313362220 cites W2970374350 @default.
• W4313362220 cites W3007389571 @default.
• W4313362220 cites W3009199988 @default.
• W4313362220 cites W3009912996 @default.
• W4313362220 cites W3011056788 @default.
• W4313362220 cites W3011176674 @default.
• W4313362220 cites W3012033061 @default.
• W4313362220 cites W3012310159 @default.
• W4313362220 cites W3012352458 @default.
• W4313362220 cites W3013821194 @default.
• W4313362220 cites W3015429854 @default.
• W4313362220 cites W3015608194 @default.
• W4313362220 cites W3037673614 @default.
• W4313362220 cites W3150889557 @default.
• W4313362220 cites W3159592735 @default.
• W4313362220 cites W3198233589 @default.
• W4313362220 cites W4200026214 @default.
• W4313362220 cites W4205640547 @default.
• W4313362220 cites W4206367754 @default.
• W4313362220 cites W4210953284 @default.
• W4313362220 cites W4220916418 @default.
• W4313362220 doi "https://doi.org/10.3390/biomedicines11010085" @default.
• W4313362220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36672593" @default.
• W4313362220 hasPublicationYear "2022" @default.
• W4313362220 type Work @default.
• W4313362220 citedByCount "2" @default.
• W4313362220 countsByYear W43133622202023 @default.
• W4313362220 crossrefType "journal-article" @default.
• W4313362220 hasAuthorship W4313362220A5003094483 @default.
• W4313362220 hasAuthorship W4313362220A5032228746 @default.
• W4313362220 hasAuthorship W4313362220A5069479089 @default.
• W4313362220 hasAuthorship W4313362220A5090298658 @default.
• W4313362220 hasBestOaLocation W43133622201 @default.
• W4313362220 hasConcept C159047783 @default.
• W4313362220 hasConcept C159110408 @default.
• W4313362220 hasConcept C181199279 @default.
• W4313362220 hasConcept C185592680 @default.
• W4313362220 hasConcept C2776714187 @default.
• W4313362220 hasConcept C2777494893 @default.
• W4313362220 hasConcept C2780035454 @default.
• W4313362220 hasConcept C41685203 @default.
• W4313362220 hasConcept C55493867 @default.
• W4313362220 hasConcept C70721500 @default.
• W4313362220 hasConcept C71924100 @default.
• W4313362220 hasConcept C86803240 @default.
• W4313362220 hasConcept C98274493 @default.
• W4313362220 hasConceptScore W4313362220C159047783 @default.
• W4313362220 hasConceptScore W4313362220C159110408 @default.
• W4313362220 hasConceptScore W4313362220C181199279 @default.
• W4313362220 hasConceptScore W4313362220C185592680 @default.
• W4313362220 hasConceptScore W4313362220C2776714187 @default.

• next